MPIA
CRL icon

Mountain Pacific Investment Advisers’s Charles River Laboratories CRL Stock Holding History

Mountain Pacific Investment Advisers’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-136,451
Closed -$20.5M – 140
2025
Q1 		$20.5M Sell
136,451
-2,159
-2% -$362K 1.53% 26
2024
Q4 		$25.6M Sell
138,610
-669
-0.5% -$129K 1.8% 24
2024
Q3 		$27.4M Sell
139,279
-2,803
-2% -$583K 1.87% 24
2024
Q2 		$29.4M Sell
142,082
-1,842
-1% -$417K 2.19% 18
2024
Q1 		$39M Buy
143,924
+1,020
+0.7% +$244K 2.18% 19
2023
Q4 		$33.8M Buy
142,904
+9,723
+7% +$1.91M 2.09% 19
2023
Q3 		$26.1M Buy
133,181
+8,821
+7% +$1.81M 1.81% 22
2023
Q2 		$26.1M Buy
124,360
+14,775
+13% +$2.94M 1.75% 22
2023
Q1 		$22.1M Buy
109,585
+2,514
+2% +$570K 1.57% 24
2022
Q4 		$23.3M Buy
107,071
+17,170
+19% +$3.75M 1.69% 21
2022
Q3 		$17.7M Buy
89,901
+16,056
+22% +$3.47M 1.38% 29
2022
Q2 		$15.8M Buy
73,845
+222
+0.3% +$54.2K 1.2% 32
2022
Q1 		$20.9M Buy
73,623
+959
+1% +$296K 1.37% 31
2021
Q4 		$27.4M Buy
72,664
+1,799
+3% +$699K 1.61% 27
2021
Q3 		$29.2M Buy
70,865
+12
+0% +$4.98K 1.79% 24
2021
Q2 		$26.2M Buy
70,853
+165
+0.2% +$55.1K 1.65% 27
2021
Q1 		$20.5M Buy
70,688
+5,060
+8% +$1.41M 1.36% 30
2020
Q4 		$16.4M Buy
65,628
+351
+0.5% +$83.6K 1.17% 32
2020
Q3 		$14.8M Buy
65,277
+55
+0.1% +$11.4K 1.21% 30
2020
Q2 		$11.4M Buy
65,222
+57,312
+725% +$9.15M 1.01% 34
2020
Q1 		$998K Buy
7,910
+1,222
+18% +$183K 0.1% 72
2019
Q4 		$1.02M Sell
6,688
-559
-8% -$77.4K 0.09% 74
2019
Q3 		$959K Sell
7,247
-6
-0.1% -$804 0.09% 74
2019
Q2 		$1.03M Sell
7,253
-45
-0.6% -$6.1K 0.09% 70
2019
Q1 		$1.06M Buy
7,298
+120
+2% +$15.8K 0.1% 68
2018
Q4 		$812K Buy
7,178
+2,964
+70% +$371K 0.09% 68
2018
Q3 		$567K Hold
4,214
– – 0.05% 86
2018
Q2 		$473K Buy
+4,214
New +$456K 0.05% 89

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Mountain Pacific Investment Advisers's CRL Position: Q2 2025 in Review

Mountain Pacific Investment Advisers sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 136,451 shares — an estimated $20.5M sold.

Mountain Pacific Investment Advisers first reported a position in CRL in Q2 2018 and held it in 28 quarters. The position peaked at $39M in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Mountain Pacific Investment Advisers reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Mountain Pacific Investment Advisers sold 136,451 Charles River Laboratories shares in Q2 2025, an estimated $20.5M.
  • Mountain Pacific Investment Advisers first reported a position in Charles River Laboratories in Q2 2018 and held it in 28 quarters.
  • Mountain Pacific Investment Advisers's Charles River Laboratories position peaked at $39M in Q1 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Mountain Pacific Investment Advisers's 13F filing for Q2 2025, filed 18 Jul 2025.